ArticleDiabetes, obesity & metabolism2026
Omnipod 5 Delivers Superior Economic Value Compared to Multiple Daily Injections: A Cost-Effectiveness Analysis in Adults With T1D From a Payer Perspective in Sweden.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Omnipod 5 Delivers Superior Economic Value Compared to Multiple Daily Injections: A Cost-Effectiveness Analysis in Adults With T1D From a Payer Perspective in Sweden.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimAnalyse the cost-effectiveness of the Omnipod 5 automated insulin delivery system versus multiple daily injections (MDI) with continuous glucose monitoring for type 1 diabetes among adults in Sweden.
methodsCost-effectiveness was analysed with the IQVIA Core Diabetes Model (version 10.0) taking the perspective of the payer in Sweden including healthcare system and combined healthcare system and societal costs. Treatment effects were derived from the RADIANT randomised controlled trial and acute complication rates from Biester et al. 2021. Treatment-specific health utilities were sourced from a Time Trade-Off (TTO) elicitation study. Incremental costs, life expectancy, quality-adjusted life-years (QALY) and incremental cost-utility ratios (ICURs) were calculated using a 50-year time horizon for the base case and sensitivity analysis tested changes in parameters including treatment effects, baseline HbA1c and time horizons.
resultsOmnipod 5 was found to be cost-effective in the base case and sensitivity analyses, with ICURs below the willingness-to-pay threshold of 500 000 SEK per QALY. In the base case Omnipod 5 was found to have lower rates of diabetes-related complications and provide 3.82 in additional QALY. Higher therapy costs with Omnipod 5 were offset by savings in the cost of complications and savings in costs associated with absenteeism. Considering direct costs only the ICUR was 201 161 SEK per QALY. Considering combined costs it was 179 247 SEK per QALY.
conclusionOmnipod 5 was found to offer superior value compared with MDI, showing cost-effectiveness for adults with type 1 diabetes in Sweden with better patient outcomes and fewer complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.